Tezspire (tezepelumab) approved in the US for severe asthma
First and only biologic to consistently and significantly reduce exacerbations in a broad population of severe asthma patients Only biologic for severe asthma approved with no phenotype or biomarker limitationsAstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma.[1] Tezspire was approved following a Priority Review by the US Food